NCT06050122 Phase 3 Completed
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Study sponsor: Sol-Gel Technologies, Ltd. · SLGL
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2026-08-20 Actual
Enrollment · participants 113 Actual
Source updated 2026-09-18 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-09-18 · 5 fields changed
Participant count type changed
Enrollment · participant count changed
− Before 140 participants (planned)
+ After 113 participants (actual)
Completion date type changed
Primary completion date changed
Recruitment status changed
− Before Active not recruiting
Check registry source
Posted 2026-08-11 · 1 field changed
Primary completion date changed
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial